Health Policy
4 articles on Health Policy, written by Shotlee and medically reviewed for clinical accuracy.
RFK Jr. Big Fan of Peptides: FDA Ban May Lift Soon
Health Secretary RFK Jr. revealed on Joe Rogan's podcast that the FDA may soon act on injectable peptides, which he supports making more accessible. Banned in 2023 for safety risks, these short amino acid chains show promise in anti-aging, muscle building, and more. Here's what peptides are and the debate surrounding them.
5 min read
GLP-1s Insurance Pricing Challenges: Q&A with Whitney Stidom
High demand for GLP-1 medications meets steep pricing and insurance hurdles. In this Q&A, eHealth's Whitney Stidom reveals why 55% of employers cover GLP-1s for diabetes but only 36% for weight loss, plus upcoming policy changes capping costs at $245 monthly for Medicare enrollees. Discover actionable insights on affordability and access.
6 min read
Expanding Access to GLP-1 Weight-Loss Meds is Essential
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
5 min read
Medicare Achieves 71% Discount on Novo's Ozempic and Wegovy
The U.S. government has successfully negotiated a 71% discount on Novo Nordisk's popular drugs Ozempic and Wegovy for Medicare beneficiaries. These price reductions, resulting from recent legislation, will be implemented in 2027, potentially saving millions of dollars.
5 min read